SCHEMBL24945842

CC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)CN)[C@@H](C)O

nearest known ligand 0.60

Predicted protein targets (top 2)

	gene	UniProt	supporting neighbours	confidence
▸	IL23R	Q5VWK5	19/20	0.60

▸	GRPR	P30550	1/20	0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL19492277	0.88	IL23R (0.66)	IL23RGRPR
SCHEMBL16286121	0.86	IL23R (0.68)	IL23RGRPR
SCHEMBL16263007	0.86	IL23R (0.63)	IL23RGRPR
SCHEMBL31546312	0.83	KISS1R (0.56)	IL23R
SCHEMBL31664384	0.82	RXFP1 (0.66)	—
SCHEMBL7156278	0.81	IL23R (0.63)	IL23RGRPR
SCHEMBL31275967	0.81	RXFP1 (0.65)	IL23RGRPR
SCHEMBL31593263	0.81	NPBWR1 (0.62)	IL23R
SCHEMBL22968949	0.81	IL23R (0.67)	IL23R
SCHEMBL30486082	0.81	IL23R (0.60)	IL23R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20230033021-A1	TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR	GLAS USA LLC	2023-02-02	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230033021-A1	TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR	ITGAL, ITGB2, ITGB1	IL23R 7/4885GRPR 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.